



**HAL**  
open science

**Novel non-carboxylic acid retinoids:  
1,2,4-oxadiazol-5-one derivatives.**

Julie Charton, Rebecca Deprez-Poulain, Nathalie Hennuyer, Anne Tailleux,  
Bart Staels, Benoit Déprez

► **To cite this version:**

Julie Charton, Rebecca Deprez-Poulain, Nathalie Hennuyer, Anne Tailleux, Bart Staels, et al.. Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.. *Bioorganic and Medicinal Chemistry Letters*, 2009, 19 (2), pp.489-92. 10.1016/j.bmcl.2008.11.040 . inserm-00360276

**HAL Id: inserm-00360276**

**<https://inserm.hal.science/inserm-00360276>**

Submitted on 10 Feb 2009

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Novel non carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.

Julie Charton<sup>a,c,d,e,\*</sup>, Rebecca Deprez-Poulain<sup>a,c,d,e</sup>, Nathalie Hennuyer<sup>b,c,d</sup>, Anne Tailleux<sup>b,c,d</sup>, Bart Staels<sup>b,c,d</sup>, Benoit Deprez<sup>a,c,d,e</sup>

<sup>a</sup>INSERM U761 Biostructures and Drug Discovery, Lille F-59006, France

<sup>b</sup>INSERM U545, Lille F-59019, France

<sup>c</sup>Faculté de Pharmacie, Université Lille 2, Lille F-59006, France

<sup>d</sup>Institut Pasteur de Lille, Lille F-59021, France

<sup>e</sup>PRIM ([www.drugdiscovery-lille.org](http://www.drugdiscovery-lille.org))

This is where the receipt/accepted dates will go; Received Month XX, 2000; Accepted Month XX, 2000 [BMCL RECEIPT]

Abstract— We have successfully obtained 1,2,4-oxadiazol-5-one bioisoteres of Am580 or Tazarotene-like retinoids. In particular compound **4** displays an EC<sub>50</sub> of 26 nM on RAR-β.

Natural and synthetic retinoids display pleiotropic effects that have led to their development as therapeutic drugs in a number of applications including acne, psoriasis and cancer<sup>1</sup>. Retinoids have a remarkable range of activities. Indeed, they regulate embryonic development, bone formation, cell differentiation and proliferation, glucose and lipid metabolism, carcinogenesis and immune function.<sup>2,3,4</sup>

The biological activities of retinoids are mediated by two types of nuclear receptors, Retinoic Acid Receptors (RARs or NR1B : RARα, RARβ and RARγ), and Retinoid X Receptors (RXRs or NR2B : RXRα, RXRβ and RXRγ). At the molecular level RARs and RXRs form heterodimers. At the cellular level, these receptors are DNA binding proteins that regulate gene transcription in response to ligand binding. The success of RAR modulation in the treatment of acute promyelocytic leukaemia (APL)<sup>5</sup> has stimulated considerable interest in the development of RAR and RXR modulators. Most potent retinoids, such as Am580 or Tazarotenic acid have an aromatic carboxylic acid moiety instead of the

polyenecarboxylic acid of retinoic acid (ATRA, Figure 1). In this family, the hydrophobic part and the linker (X) can be varied with retention of high activity. Tazarotene, an RAR-β,γ selective acetylenic retinoid, was chosen for development as a topical agent for psoriasis and acne. Am580 (RAR-α selective) has powerful and selective cyto-differentiating effects on APL.<sup>6,7</sup>





Figure 1: General structure of retinoids and examples.<sup>2</sup>


\* Corresponding author. Tel.: +33(0)320 964928; fax: +33(0)320 964 709, email [julie.charton@univ-lille2.fr](mailto:julie.charton@univ-lille2.fr)

Various acidic heterocycles are classically used by medicinal chemists as carboxylic acid bioisosteres.<sup>8</sup> Tetrazole is a common bioisostere of the carboxylic acid group but in the particular case of retinoids led to loss of activity.<sup>9</sup> On the contrary, thiazolidinedione moiety has been described by Tashima et al. to be an effective replacement of the carboxylic acid (Figure 2a).<sup>10,11</sup> More recently, bioisosteric replacement of carboxylic acid with a tropolone ring is reported (Figure 2b).<sup>12,13</sup>




**Figure 2** : Non-Benzoic Acid Retinoids.

Another example of acidic heterocycle is the 1,2,4-oxadiazol-5-one ring, found in AT1 antagonists<sup>14</sup>, COX inhibitors<sup>15</sup>, PLA2 inhibitors<sup>16</sup> and modulators of GluR<sup>17</sup>. This heterocycle can replace carboxylic acids but displays geometrically different protomers and slightly different physico-chemical properties. Compounds bearing this heterocycle have different lipophilic properties that may translate into improved bioavailability compared with their carboxylic analogues. Indeed,  $\Delta\log D_{7.4}$  between benzoic acid and 3-phenyl-1,2,4-oxadiazol-5-one = 0.7 log unit, the oxadiazolone being more hydrophobic than its carboxylic counterpart.<sup>18</sup> In our project aiming at synthesizing various analogues of pharmacologically active carboxylic acids, we explored the replacement of the carboxylic acid function by the 1,2,4-oxadiazol-5-one moiety in two series of retinoids: analogues of the tazarotene, a RAR- $\beta,\gamma$  selective acetylenic retinoid, and Am580, an RAR- $\alpha$  selective retinoid (Figure 3).



**Figure 3**: Generic structure of the potential retinoid 1,2,4-oxadiazol-5-one derivatives.


First, we investigated the synthesis of tazarotenic acid analogues.<sup>19</sup> Precursors **1** and **2** were synthesized as previously described from the corresponding nitrile in two steps (Scheme 1).<sup>20</sup>



**Scheme 1**. Reaction conditions: i)  $\text{NH}_2\text{OH}\cdot\text{HCl}$ , DIEA, EtOH, reflux, 8 hrs, (1a: 75%, 2a: 95%). ii) CDI, DBU, dioxane, 110°C, 2hrs, (1: 80%, 2: 80%).

We have recently reported a strategy for solid phase synthesis of acetylenic derivatives of 3-aryl-1,2,4-oxadiazol-5-one thanks to a Sonogashira reaction.


Compound **1** was thus grafted on resin and then reacted with 6-ethynyl-1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthalene **3** to yield compounds **4** (Scheme 2).



**Scheme 2**.


Reaction conditions: i) trimethylsilylacetylene (1.3 eq),  $\text{PdCl}_2(\text{PPh}_3)_2$  (0.05 eq), CuI (0.1 eq),  $\text{NEt}_3$ , 70°C, 12 hrs. ii) KOH (0.1N), Isopropanol, 12hrs, room temp. iii) alkyne (10 eq),  $\text{PdCl}_2(\text{PPh}_3)_2$  (1.1 eq), CuI (2.2eq), DIEA (30 eq), DMF, rt, 3 hrs then 5% TFA/ $\text{CH}_2\text{Cl}_2$ , rt, 3 hrs

In the search of a more cost-effective synthesis, we also developed the first solution Sonogashira coupling with an unprotected 1,2,4-oxadiazol-5-one ring. Such strategy has been used for Suzuki-Miyaura reactions<sup>21</sup> and successfully applied for the synthesis of compounds **5-7** (Scheme 3).




**Scheme 3**. Reaction conditions: i) **1** or **2**,  $\text{PdCl}_2(\text{PPh}_3)_2$ , CuI,  $\text{NEt}_3$ , DMF, 80°C, 7 hrs, (**5**: 50%, **6**: 83%, **7**: 56%).

Some carboxylic acid analogues described in literature were also synthesized like compounds **8** and **9** in order to compare retinoidal activity of our oxadiazolone derivatives with known retinoic compounds.



**Scheme 4**. Reaction conditions: i) Alkyne (1.2 eq),  $\text{PdCl}_2(\text{PPh}_3)_2$  (0.05 eq), CuI (0.1 eq.),  $\text{NEt}_3$ , DMF, 80°C, 5 hrs, **8a** : 52 %, **9** : 20%, ii) NaOH (2 eq), EtOH, **8**: 100%.

Am580 and its 1,2,4-oxadiazol-5-one analog **10** were synthesized as described in Scheme 5.







**Scheme 5**. Reaction conditions: i)  $\text{H}_2\text{N}-\text{C}_6\text{H}_4-\text{CO}_2\text{Et}$ ,  $\text{NEt}_3$ , THF, rt, 3 hrs, 85%. ii) NaOH, EtOH,  $\text{H}_2\text{O}$ , 40°C, 12hrs, 90%. iii)  $\text{H}_2\text{N}-\text{C}_6\text{H}_4-\text{CN}$ ,  $\text{NEt}_3$ , THF, rt, 12 hrs, **10a**: 98%. iv)  $\text{NH}_2\text{OH}\cdot\text{HCl}$ , DIEA, EtOH, reflux, 6 hrs, **10b**: 91%. v) CDI, DBU, dioxane, 110 °C, 2hrs, **10**: 44%.

The retinoidal activities of the synthesized compounds were examined in terms of potency and efficacy and

results are presented in Table 1. Chimeric receptors RAR-Gal4 where RAR ligand-binding domain (LBD) fused to the DNA binding domain (DBD) of the yeast transcription factor GAL4 and reporter gene containing a GAL4 response element-driven

luciferase activity have been transiently transfected. Mammalian cells did not contain GAL, only the transfected RAR-GAL4 chimeric receptors can activate the reporter gene, eliminating interference from endogenous nuclear receptors.<sup>22</sup>

**Table 1:** Transcriptional activation assay data.<sup>a</sup>

Cpds		RAR- $\alpha$		RAR- $\beta$		RAR- $\gamma$	
		EC <sub>50</sub> (nM)	Eff(%)	EC <sub>50</sub> (nM)	Eff(%)	EC <sub>50</sub> (nM)	Eff(%)
<b>8</b>		>1000	- <sup>b</sup>	10.0	35 <sup>c</sup>	10.0	44 <sup>c</sup>
<b>5</b>		>1000	- <sup>b</sup>	820.0	34	>1000	- <sup>b</sup>
<b>6</b>		>1000	- <sup>b</sup>	>1000	- <sup>b</sup>	>1000	- <sup>b</sup>
<b>9</b>		0.6	53	0.3	83	0.6	125
<b>4</b>		>1000	- <sup>b</sup>	26.0	50	91.0	48
<b>7</b>		>1000	- <sup>b</sup>	>1000	- <sup>b</sup>	>1000	- <sup>b</sup>
Am580		0.3	43	8.6	46	13.0	43
<b>10</b>		520.0	40	>1000	- <sup>b</sup>	>1000	- <sup>b</sup>
Tazarotene		63.0	54	0.8	57	40.0	72
ATRA		17.0	100	12.0	100	0.2	100

<sup>a</sup> The data are expressed as averages of % efficacy and EC<sub>50</sub>. Eff. : efficacy is relative to ATRA defined as 100%.

<sup>b</sup> <10% at 10 $\mu$ M.

<sup>c</sup> Efficacy is relative to Tazarotene defined as 100%.

Tazarotene and its analogue **8** are RAR- $\beta,\gamma$  selective acetylenic retinoids, whereas analogue **9** is very active on the three subtypes. Interestingly, 1,2,4-oxadiazol-5-one **4** and **5** activities differ from their carboxylic acid analogues. Indeed, compound **5** is slightly active on RAR- $\beta$ . Compound **4**, though nanomolar on RAR- $\beta$  (EC<sub>50</sub> = 26 nM), is less active than **9** but displays a better selectivity on RAR- $\beta,\gamma$  subtypes and an efficacy comparable with tazarotene. As expected, bended analogue **7** is not active since it is not linear enough to fit the RAR pharmacophore. In the second series, compound **10** is active on RAR- $\alpha$  with a similar efficacy to that of Am580 (40 versus 43 %). In the light

of these results, both compounds **4** and **10** could be good starting points for further optimization.

All these compounds were checked for cross-reactivity with the retinoid X receptor (RXR  $\alpha$ ,  $\beta$ ,  $\gamma$ ) and found to be inactive.

In conclusion, we have described the solid-phase or solution-phase syntheses of a new series of non carboxylic acid RAR ligands. We have shown that the 1,2,4-oxadiazol-5-one moiety can act as a bioisostere of the carboxylic acid function in retinoid structures. In particular the retinoidal activity of compound **4** (RAR-

$\beta,\gamma$  selective) is significant, considering that replacement of the carboxylic acid in retinoid structures with bioisosteric functional groups is generally ineffective. These non carboxylic acid type RAR ligands may exhibit different pharmacological behaviors from classical carboxylic acid compounds, as well as unique biological activity, and they may provide further scope for clinical applications.

### Acknowledgements

We are grateful to the Institutions that support our laboratory (Inserm, Université de Lille2 and Institut Pasteur de Lille). Data management was performed using Pipeline Pilot™ from Scitegic. We thank also the following Institutions or companies: CAMPLP and VARIAN.inc. This project was supported by the Fondation pour la Recherche Medicale (FRM) - Nord-Pas-de-Calais.

### Supplementary data

Supplementary data associated with this article can be found for the online version.

- 
- <sup>1</sup> Altucci, L.; Leibowitz, M. D.; Ogilvie, K. M.; de Lera, A. R.; Gronemeyer, H. *Nat Rev Drug Discov* **2007**, *6*, 793.
  - <sup>2</sup> Thacher, S. M.; Vasudevan, J.; Chandraratna, R. A. *Curr Pharm Des* **2000**, *6*, 25.
  - <sup>3</sup> Altucci, L.; Gronemeyer, H. *Nat Rev Cancer* **2001**, *1*, 181.
  - <sup>4</sup> de Lera, A. R.; Bourguet, W.; Altucci, L.; Gronemeyer, H. *Nat Rev Drug Discov* **2007**, *6*, 811.
  - <sup>5</sup> Lengfelder, E.; Saussele, S.; Weisser, A.; Büchner, T.; Hehlmann, R. *Critical Reviews in Oncology/Hematology* **2005**, *56*, 261.
  - <sup>6</sup> Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K.; Himi, T. *J. Med. Chem.* **1988**, *31*, 2182.
  - <sup>7</sup> Gianni, M.; Li Calzi, M.; Terao, M.; Guiso, G.; Caccia, S.; Barbui, T.; Rambaldi, A.; Garattini, E. *Blood* **1996**, *87*, 1520.
  - <sup>8</sup> Wermuth, C.G. in *The Practice of Medicinal Chemistry*, edited by Wermuth, C.G. 2nd Edition, 2003, Academic Press, London, pp 189-214.
  - <sup>9</sup> Dawson, M. I.; Hobbs, P. D.; Kuhlmann, K.; Fung, V. A.; Helmes, C. T.; Chao, W.-R. *J. Med. Chem.* **1980**, *23*, 1013.
  - <sup>10</sup> Tashima, T.; Kagechika, H.; Tsuji, M.; Fukasawa, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K. *Chem Pharm Bull (Tokyo)* **1997**, *45*, 1805.
  - <sup>11</sup> Ebisawa, M.; Kawachi, E.; Fukasawa, H.; Hashimoto, Y.; Itai, A.; Shudo, K.; Kagechika, H. *Biol Pharm Bull* **1998**, *21*, 547.
  - <sup>12</sup> Ebisawa, M.; Ohta, K.; Kawachi, E.; Fukasawa, H.; Hashimoto, Y.; Kagechika, H. *Chem Pharm Bull (Tokyo)* **2001**, *49*, 501.
  - <sup>13</sup> Kagechika Hiroyuki Nerima-Ku, EP 1 357 104 A1
  - <sup>14</sup> Kohara, Y.; Kubo, K.; Imamiya, E.; Wada, T.; Inada, Y.; Naka, T. *J Med Chem* **1996**, *39*, 5228.
  - <sup>15</sup> Boschelli, D. H.; Connor, D. T. May 19, **1992**; Patent

---

US 5,114,958.

- <sup>16</sup> Dong, C.-Z.; Ahamada-Himidi, A.; Plocki, S.; Aoun, D.; Touaibia, M.; Meddad-Bel Habich, N.; Huet, J.; Redeuilh, C.; Ombetta, J.-E.; Godfroid, J.-J. *Bioorg. Med. Chem.* **2005**, *13*, 1989.
  - <sup>17</sup> Valgeirsson, J.; Nielsen, E. O.; Peters, D.; Mathiesen, C.; Kristensen, A. S.; Madsen, U. *J Med Chem* **2004**, *47*, 6948.
  - <sup>18</sup> Measured with shake-flash method, UV detection.
  - <sup>19</sup> Patent US5,349,105, Allergan, issued 20<sup>th</sup> September 1994.
  - <sup>20</sup> Charton, J.; Cousaert, N.; Bochu, C.; Willand, N.; Deprez, B. and Deprez-Poulain, R. *Tetrahedron Lett.* **2007**, *48*, 1479.
  - <sup>21</sup> Stansfield, I.; Pompei, M.; Conte, I.; Ercolani, C.; Migliaccio, G.; Jairaj, M.; Giuliano, C.; Rowley, M. and Narjes, F. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 5143.
  - <sup>22</sup> Cell culture. Cos-7 cells were obtained from ATCC (CRL-1651). Cells were maintained in standard culture conditions (Dulbecco's modified Eagle's minimal essential medium supplemented with 10% fetal calf serum at 37°C in a humidified atmosphere of 5% CO<sub>2</sub>/95% air). Medium was changed every 2 days.
- Effect of compounds on RARs transcriptional activity using chimaeric protein constructs. Cos-7 cells were seeded in 60mm dishes in DMEM supplemented with 10% FCS and incubated at 37°C for 16h prior transfection. Cells were transfected in DMEM 10% FCS, using jetPEI™ transfection reagent, with reporter (pGal5-TK-pG13) and expression plasmids (pGal4-hRAR $\alpha$ ,  $\gamma$ , or  $\beta$ ). Cells were incubated at 37°C. After 24h, cells were trypsinised and seeded in 96-well plates and incubated for 6h in DMEM containing 0.2% FCS. Cells were then incubated 16h in DMEM 0.2% FCS and increasing concentrations of the compounds tested or vehicle (DMSO). At the end of the experiments, cells were washed once with PBS and the luciferase and the  $\beta$ -galactosidase assays were performed.